A 8031366
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`
`January 22, 2020
`
`THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
`RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
`JANUARY 12, 2004.
`
`By Authority of the
`Under Secretary of Commerce for Intellectual Property
`and Director of the United States Patent and Trademark Office
`
`M. TARVER
`Certifying Officer
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 1
`
`

`

`Substitute for PTO-1595/Rev. 10/e2) "Recordation form Cover Sheet"
`OMB No. 0651-0027 (exp. 6/30/2005)
`
`o
`
`PLEASE RECORD T
`
`II | |11 |i} tirol i I }| ||1 | I ~il I |l
`
`0 i - i 4 - 2004
`i;iiiii!!IIiiiiii 111111111 I1111i 1111111 i1111ii11111
`! 02645388
`
`Patent Case No. 20907
`
`U.S. DEPARTMENT OF COMMERCE
`U.S. PATENT AND TRADEMARK OFFICE
`
`ADEMARK OFFICE:
`R COPY THEREOF.
`
`1. Name(s) of Conveying party(ies):
`Scott D. Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm MacCoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
`
`Additional name(s) of conveying party(ies) attached?
`
`[--] Yes IX] No
`
`2. Nature of conveyance:
`
`X~ Assignment
`
`L~ Merger
`
`[--1 Security Agreement
`
`[--] Change of Name
`
`[~ Other:
`
`¯
`
`-
`
`3. Name and address of receiving patjt~ es)~
`~ t~
`
`Name: MERCK & Co., INC.
`
`Internal Address: RY60-30
`
`~~
`
`---
`
`Street Address: P.O. Box 2000
`
`o*’,,
`
`,.:~
`
`,"’,
`
`.?:
`i~.
`,.
`’
`
`City & State: RAHWAY, NEW JERS~_y.
`
`Zip/Postal Code: 07065-0907
`
`~--~..,
`
`..o
`"~....:.
`:~.-_. Y-:
`
`Execution Date: May 31,2002
`’~
`
`__
`
`Additional name(s) &
`addresses attached?
`
`[--] Yes
`
`[X--] No
`
`4. Application number(s) or patent number(s) are as follows:
`(a) Patent Application No(s). 10/189,603
`and titled:
`BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR
`PREVENTION OF DIABETES
`
`, filed on July 5, 2002
`
`(b) If this document is being filed together with a new application, the execution date of the application is:
`
`5.
`
`Name & address of party to whom correspondence
`concerning documents should be mailed:
`Name: Philippe L. Durette
`
`Additional numbers attached? [--] Yes [~ No
`6. Total no. of applications & patents involved: [ 1 I
`
`7. Total fee (37 CFR 3.41) ................................. $ 40.00
`
`L
`
`Internal Address:
`
`City & State:
`
`PATENT DEPARTMENT
`MERCK & CO.1 INC.
`P.O. BOX ;~.000 -- RY60-30
`RAHWAY, N.J. Zip: 07065-0907
`
`F-~ Enclosed
`
`[~ The Director is hereby authorized to
`charge deposit account number 13-2755 for any
`fees which may be required or to credit any
`overpayment.
`
`DO NOT USE THIS SPACE
`
`8. Statement and signature:
`T othe best of my knowledge and belief, the foregoing info~ d L/"~/~--./-~.~...[, ~--~
`r~an correct .a~any attached copy ~. a true
`
`copy of the original document.
`Philippe L. Durette
`Name of Person Signing
`
`Reg, No, ,35,,!25
`
`~
`- ~ Jan 8, 200~
`.
`Date
`~i/*’Y Signature
`
`Total number of pages including cover sheet, attachments, and documents:l 3
`
`NOTE: Send to Mail Stop Assignment, Recordation Services ~ ~ ,
`
`I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelopeQ ’~’
`addressed’to: Director of the U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the US. Patent,.&nd "~" }
`Trademark Office on:
`i
`~,.
`
`Name (Print/Type) Denise K. Brown
`i
`~
`! ............................................................................................................................................................................................................................................................. ~ ..4
`Signature .(~ n .." .... ~J~ ~ .~ ..,,~ . iDatell/8/2004
`
`~ ~ !
`
`IN DUPLICATE
`
`Computer generated form Merck & Co., Inc. "Record~Ar~*nents Folder)~y’17,~03
`
`REEL: 014868 FRAME: 0413
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 2
`
`

`

`ASSIGNMENT AND AGREEMENT
`
`PATENT
`
`JOINT Merck Case 2_0.90__7_ .....
`
`U.S. Serial No.
`
`Filing Date
`
`For value received, we,
`
`Scott D. Edmondson, Michael H, Fisher, Dooseop Kim, Malcolm MacCoss, Emma R. Parmee, Ann ,
`E. Weber and Jinyou Xu
`
`of
`
`124 W. 109th Street, New York, NY 10025; Road 3, Old York Road, Ringoes, NJ 08551; 77 Sandy Hill Road, Westfield, NJ 07090;
`48 Rose Court, Freehold, NJ 07728; 1423 Grayrnill Drive, Scotch Plains, NJ 07076; 1974 Duncan Drive, Scotch Plains, NJ 07076;
`61 Clydesdale Road, Scotch Plains, NJ 07076
`
`hereby sell, assign and transfer to MERCK& CO., Inc., a corporation of the State of New Jersey, having an office at Lincoln Avenue,
`
`City of Rahway, State of New Jersey, and its successors, assigns and legal representatives, the entire right, title and interest, for all
`
`countries, in and to certain inventions relating to
`
`BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF
`DIABETES
`
`described in an application for Letters Patent of the United States, executed by us on even date herewith, and in provisioiud application(s)
`
`Serial No. 60/303,474 filed on 07/06/2001 ; Serial No.
`
`filed on
`
`; Serial No.
`
`filed on
`
`(if apjplicable), and all the rights and privileges, including any and all benefits under the International Convention for the Protection of
`
`Industrial Property under any and all Letters Patents which may be granted therefor, and under any and all extensions, divisionals,
`
`reissues and continuations of said Letters Patents.
`
`We request that any and all Patents for said inventions be issued to said assignee, its successor, assigns and legal
`
`representatives, or to such nominees as it may designate.
`
`We agree that, when requested, we Will, without charge to said assignee but at its expense, sign all papers, take all rightful
`
`oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining Patents for said inventions in any
`
`and all countries and for vesting title thereto in said assignee, its successors, assigns and legal representatives or nominees.
`
`We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed
`
`are free and clear of any encumbrance, and that we have full right to convey the same as herein expressed.
`
`We hereby authorize our attorney, J.Eric Thies
`
`or an attorney with Power of Attorney in this application,
`
`of the said MERCK & CO., lnc., to insert Serial No., and Filing Date of said application(s) when known.
`
`~ ~k,] ~
`
`Scott !?~ondson
`
`-
`
`-
`
`Emma R. Parmee
`
`Jinyou Xu
`
`this
`
`day of
`
`I ,
`
`Michael H. Fisher
`
`I@
`dT,- /4,,
`
`Ann E. Weber
`
`Computer generated form "Assignment Merck - Joint" (Assignmenls Folder) blerck & Co., Inc. 3120/2002
`
`Page 1 of 2
`
`PATENT
`REEL: 014868 FRAME: 0414
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 3
`
`

`

`ASSIGNMENT AND AGREEMENT
`
`PATENT
`
`JOINT Merck Case 20907
`
`U.S. Serial No.
`
`Filing Date
`
`Signed at
`
`this
`
`day of
`
`STATE OF NEW JERSEY
`
`Countyof Union
`
`"
`
`Personally appeared before me the above-named
`
`Scott D. Edmondson Dooseop Kim
`Malcolm MacCoss Ann E. Weber
`
`Emma R. Parmee Michael H. Fisher
`Jinyou Xu
`
`to me known and known to me to be the person(s) who executed the foregoing instrument and acknowledged said instrument to be
`
`their free act and deed this ~LI__ day of ~O~[ ,
`
`County of
`
`SS.
`
`Personally appeared before me the above-namexl
`
`t.)-
`
`"
`
`No,a, p,,l, lic
`
`MARYANN I. HAAS
`NOTARY PUBLIC OF NEW JERSF.,Y
`MY COMMISSION EXP|RESSEPT IB~200~
`
`to me known and known to me to be the person(s) who executed the foregoing instrument and acknowledged said instrument to be
`
`their free act and deed this
`
`day of
`
`, __
`
`Nota¢y Public
`
`Ct)nlpuw.r generated form "Assignment Meek - Joint" (Assignn~ents Folder) Merck & Co., lee. 3/20/2002
`
`Page 2 of 2
`
`RECORDED: 01/t2/2004
`
`PATENT
`REEL: 014868 FRAME: 0415
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 4
`
`

`

`PTO-1683
`(Rev. 7-96)
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 5
`
`

`

`A 8031366
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`
`January 22, 2020
`
`THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
`
`RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
`
`JANUARY 28, 2010.
`
`By Authority of the
`
`Under Secretary of Commerce for Intellectual Property
`and Director of the United States Patent and Trademark Office
`
`M. TARVER
`Certifying Officer
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 6
`
`

`

`[[
`
`Electronic Version v1.1
`Stylesheet Version v1.1
`
`PATENT ASSIGNMENT’
`
`II
`
`SUBMISSION TYPE:
`
`NEW ASSIGNMENT
`
`NATURE OF CONVEYANCE:
`
`CHANGE OF NAME
`
`CONVEYING PARTY DATA
`
`MERCK & CO., INC.
`
`RECEIVING PARTY DATA
`
`Name
`
`Name:
`
`1MERCK SHARP & DOHME CORP.
`
`Street Address:
`
`City:
`
`State/Country:
`
`Postal Code:
`
`11126 EAST LINCOLN AVENUE
`
`II~HVVAY
`IINEWJERSEY
`1107062
`
`PROPERTY NUMBERS Total: 210
`
`Property Type
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`501078569
`
`I!
`116534506
`116538002
`116544213
`!16544753
`
`116544967
`
`I1~°°~
`I1~.~°=~
`
`I1~.~.°=
`11~.8~
`I1°~=°~
`
`II
`
`E xecution Date
`
`I I
`1111,o2,2ooo
`
`Number
`
`PATENT
`REEL: 023861 FRAME: 0349
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 7
`
`

`

`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`6562823
`
`6565813
`
`6566385
`
`6569434
`
`6569879
`
`6573261
`
`6583142
`
`6586423
`
`6586424
`
`6586452
`
`6589318
`
`6593108
`
`6593346
`
`6599718
`
`6602697
`
`6605720
`
`6610692
`
`6610722
`
`6610822
`
`6616931
`
`6617426
`
`6623755
`
`6630510
`
`6632625
`
`6632818
`
`6632823
`
`6632836
`
`6638347
`
`6638930
`
`6638942
`
`6639071
`
`6642237
`
`6645726
`
`6645738
`
`iJ
`
`PATENT
`REEL:023861 FRAME:0350
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 8
`
`

`

`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`6645961
`
`6645974
`
`6645997
`
`6646130
`
`6649649
`
`6653097
`
`6656719
`
`6664375
`
`6673831
`
`6673935
`
`6680340
`
`6682908
`
`6686363
`
`6689366
`
`6689574
`
`6689761
`
`6689873
`
`i6692764
`
`6693165
`
`6693184
`
`6699871
`
`6706885
`
`6713508
`
`6726021
`
`6727244
`
`6730690
`
`6733767
`
`6733993
`
`6743622
`
`6750041
`
`6750220
`
`6762042
`
`6767908
`
`6774138
`
`6777395
`
`11
`
`PATENT
`REEL:023861 FRAME:0351
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 9
`
`

`

`Patent Number:
`
`Patent Number:
`
`I Patent Number:
`I Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`I Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`6777580
`
`6784190
`
`6787351
`
`6790445
`
`6794393
`
`6794405
`
`16797476
`
`6797492
`
`6800452
`
`6800647
`
`6809199
`
`6812234
`
`6814895
`
`6818658
`
`6825322
`
`6835548
`
`6835837
`
`6835860
`
`6838291
`
`6841157
`
`6841367
`
`6841382
`
`6849636
`
`6852727
`
`6852738
`
`6864358
`
`6864383
`
`6870055
`
`6870067
`
`6872724
`
`6906320
`
`6908615
`
`6919343
`
`6919351
`
`6921759
`
`ii
`
`PATEN-
`REEL: 023861 FRAME: 0352
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 10
`
`

`

`Patent Number:
`
`~atent Number:
`
`~atent Number:
`
`~atent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`~atent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`I Patent Number:
`
`16939964
`
`I16939966
`
`116946474
`
`116953790
`
`116958334
`
`116972295
`
`116991795
`
`7001995
`
`~’012084
`
`~015235
`
`7022841
`
`7O26316
`
`7029878
`
`7033789
`
`7033797
`
`7034026
`
`~034167
`
`7053089
`
`7056909
`
`7057051
`
`7060294
`
`7060463
`
`7067258
`
`7071159
`
`7071330
`
`7084134
`
`17084156
`
`7091211
`
`7091216
`
`7091230
`
`7091380
`
`II 7094767
`
`II,oo =o PA’I’ N
`
`REEL: 023861 FRAME: 0353
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 11
`
`

`

`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:.
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`7098239
`
`7101871
`
`117101884
`
`7105499
`
`J[7105533
`
`J17105548
`
`JL7109191
`
`7109204
`
`J[7109217
`
`J[7115597
`
`7115628
`
`7125865
`
`7125873
`
`7125887
`
`7125888
`
`7132277
`
`7132401
`
`7135307
`
`7148026
`
`117148236
`
`117151196
`
`7157443
`
`7157490
`
`7160886
`
`7163799
`
`7163951
`
`7164003
`
`7166614
`
`7169788
`
`7169895
`
`=l
`
`PATENT
`REEL:023861 FRAME:0354
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 12
`
`

`

`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`Patent Number:
`
`CORRESPONDENCE DATA
`
`7176008
`
`7179802
`
`7186723
`
`7186746
`
`7186838
`
`7189722
`
`7192949
`
`7192954
`
`7193070
`
`7196076
`
`7196079
`
`7196082
`
`7196095
`
`7196106
`
`7196113
`
`i7196163
`
`7198910
`
`7199232
`
`7199240
`
`7202224
`
`Fax Number:
`(212)246-8959
`Correspondence will be sent ~a US Mail when the fax attempt is unsuccessful.
`Phone:
`Email:
`Correspondent Name:
`Address Line 1:
`Address Line 4:
`
`212-708-1870
`
`Ibryer@ladas.com
`
`Lanning G. Bryer
`
`26 West 61st Street
`
`New York, NEW YORK 10023
`
`I NPA 090242:753
`I Lanning G. Bryer
`
`ATTORNEY DOCKET NUMBER:
`
`NAME OF SUBMITTER:
`
`Total Attachments: 21
`source=Merck-Pages74-87#page 1 .tif
`source=Merck-Pages74-87#page2.tif
`source=M erck-Pages74-87#page3.tif
`source= Merck-Pages74-87#page4.tif
`source = Merck-Pages74-87#page5.tif
`source=Merck-Pages74-87#page6.tif
`
`PATENT
`REEL: 023861 FRAME: 0355
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 13
`
`

`

`source= Merck-Pages74-87#page7.tif
`source =Merck-Pages74-87#page8.tif
`source=Merck-Pages74-87#page9.tif
`source=Merck-Pages74-87#page10.tif
`source =Merck-Pages74-87#page 11 .tif
`source= Merck-Pages74-87#page 12.tif
`source=Merck-Pages74-87#page 13.tif
`source=Merck-Pages74-87#page 14.tif
`source=Merck-Pages74-87#page15.tif
`source=Merck-Pages74-87#page 16°tif
`source=Merck-Pages74-87#page 17.tif
`source=Merck-Pages74-87#page18.tif
`source=Merck-Pages74-87#page19.tif
`source=Merck-Pages74-87#page20.tif
`source =M erck-Pages74-87#page21 .tif
`
`PATENT
`REEL: 023861 FRAME: 0356
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 14
`
`

`

`L
`
`STATE OF NEW JERSEY
`DEPARTMENT OF TREASURY
`FILING CERTIFICATION (CERTIFIED COPY)
`
`MERCK SHARP & DOHME CORP.
`
`I, the Treasurer of the State of New Jersey,
`do hereby certify, that the above named business
`did file and record in this department the below
`listed document(s) and that the foregoing is a
`true copy of the
`Restated Certificate With A Name Change
`as thesame is taken from and compared with the
`original(s) filed in this office on the date set
`forth on each instrument and now remainin on "te
`"and of record in my office, g f!
`
`IN TESTIMONY WHEREOF, I have
`
`hereunto set my hand and affixed
`
`my Official Seal at Trenton, this
`23rd day of November, 2009
`
`Certificate Number: 115810389
`
`Verify this certificate online at
`
`https://www l.state.nj.us/TYTR_StandingCert/JSP/Verify_ Cert.jsp
`
`R. David Rousseau
`State Treasurer
`
`Page l of 1.
`
`PATENT
`REEL: 023861 FRAME: 0357
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 15
`
`

`

`CERTIFICATE OF ADOPTION
`OF
`RESTATED CERTIFICATE OF INCORPORATION
`OF
`MERCK & CO., INC.
`(ID Number: 5934701000)
`
`Merck & Co., Inc., a corporation organized and existing under the laws of the State of
`New Jersey (the "Corporation"), to amend and restate its Certificate of Incorporation pursuant to
`Section 14A:9-5 of the New Jersey Business Corporation Act (the "NJBCA"), hereby eertifies as
`follows:
`
`FIRST: The name of the Corporation is Merck Sharp & Dohme Corp.
`
`SECOND: The Restated Certificate of Incorporation attached hereto (the "Restated
`Certificate") was adopted by the shareholders of the Corporation on August 7, 2009 as part of
`their approval of the Agreement and Plan of Merger, dated as of March 8, 2009, by and among
`the Corporation, Sehering-Plough Corporation, SP Merger Subsidiary One, Inc. (formerly known
`as Blue, he.), and SP Merger Subsidiary Two, Inc. (formerly known as Purple, Inc.), and
`pursuant to Section 14A:10-1 and Section 14A:10-4.1 of the NJBCA.
`
`THIRD: The number of shares entitled to vote on the adoption of the Restated
`Certificate was 2,108,780,449 shares of Common Stock, of which 1,399,114,521 voted for the
`Restated Certificate as part of their approval of the Agreement and Plan of Merger, and
`5,686~148 voted against the Restated Certificate. No shares of any class or series were entitled to
`vote thereon as a class.
`
`FOURTH: This Certificate of Adoption shall become effective on November 3, 2009 at
`4:02 p.m.
`y
`q-
`
`t ox"O b, O 7
`qv S"-Ot, a g
`5"/: b°q
`
`PATENT
`REEL: 023861 FRAME: 0358
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 16
`
`

`

`~CK & co. ~C.
`
`Title: Senior V~ce President, Sscrstary
`and Ass~s~ut Can~ral Counssl
`
`e~f to ~ ofAdotz~m ~ Cen~y~(cid:128)~ ofl.cor~o~
`
`PATENT
`REEL: 023861 FRAME: 0359
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 17
`
`

`

`RESTATED CERTIFICATE OF INCORPORATION
`
`OF
`
`MERCK & CO., INC.
`(ID Number: 5934701000)
`
`Merck & Co., Inc., a corporation organized and existing under the laws of the
`State of New Jersey (the "Corporation"), restates and integrates its Restated Certificate of
`Incorporation, as heretofore amended, and also substantively amends such Restated Certificate of
`Incorporation, to read in full as herein set forth:
`
`FIRST: The name of the Corporation is Merck Sharp & Dohme Corp.
`
`SECOND: The purpose for which the Corporation is organ~d is to engage in
`any activity within the purposes for which corporations may be organized under the New Jersey
`Business Corporation Act.
`THIRD: The total number of shares of capital stock which the Corporation shall
`have authority to issue is 100 shares of common stock, $0.01 par value per share, Shares of
`capital stock of the Corporation may be issued by the Corporation from time to time for such
`legally sufficient consideration as may be fixed from time to time by the Board of Dkectors.
`
`FOURTH: In furtherance and not in limitation of the general powers conferred
`by the laws of the State of New Jersey, the Board of Directors is expressly authorized to make,
`alter or repeal the bylaws of the Corporation, except as specifically stated therein.
`
`FIFTH: The Corporation reserves the fight to amend, alter, change or repeal any
`provision contained in the Certificate of Incorporation, in the manner now or hereafter prescribed
`by statute, and all rights conferred upon shareholders herein are granted subject to this
`reservation.
`
`SIXTH: The Corporation shall, to the full extent permitted by the New Jersey
`Business Corporation Act, as it may be amended from time to time, indemnify all persons whom
`it may indemnify pursuant thereto.
`SIWENTR: No director or officer of the Corporation shall be personally liable
`to the Corporation or its shardxolders for damages for breach of any duty owed to the
`Corporation or its shareholders, except that such provision shall not relieve a dixeetor or officer
`from liability for any breach of duty based upon an act or omission (a) in breach of such person’s ¯
`duty of loyalty to the Corporation or its shareholders, (b) not in good faith or involving a
`knowing violation of law or (c) resulting in receipt by such person og any improper personal
`benefit. As used in this artieh, an act or omission in breach era person’s duty of loyalty means
`art act or omission which that person knows or believes to be contrary to the best interests of the
`Corporation or its shareholders in connection with a matter in which he has a material conflict of
`interest.
`
`PATENT
`REEL: 023861 FRAME: 0360
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 18
`
`

`

`EIGHTH: Except as otherwise required by the laws of the State of New Jersey,
`the shareholders and directors shall have the power to hold their meetings and to keep the books,
`documents, and papers of the Corporation outside of the State of New Jersey, and the
`Corporation shall have the power to have one or more offices within or without the State of New
`Jersey, at such places as may be from time to time designated by the bylaws or by resolution of
`the shareholders Or directors. Elections of directors need not be by ballot unless the bylaws of
`the Corporation shah so provide.
`
`NINTH: The address of the Corporation’s current registered office in the State of
`New Jersey is 820 Bear Tavern Road, City of West Trenton, County of Mercer, State of New
`Jersey, 08628, and the name of the Corporation’s registered agent at such address is The
`Corporation Trust Company.
`TENTH: The number of directors constituting the current Board olD,rectors of
`the Corporation is fifteen (15). The names and addresses of said directors are as follows:
`
`Leslie A. Brim
`
`Thomas IL Cech, Ph.D.
`
`Richard T. Clark
`
`Thomas H. Glocer
`
`Steven F. Goldstone
`
`William B. Harrison, Jr.
`
`Harry R. Jacobsen, M.D.
`
`William N. Kelley, M.D.
`
`Rochelle B. Lazarus
`
`Carlos E. Represas
`
`Thomas E. Shenk, Ph.D
`
`Anne M. Tatlock
`
`Samuel O. Thier, M.D.
`
`435 Devon Park Drive, 700 Building
`Wayne, Pennsylvania 19087
`University of Colorado, Boulder
`Boulder, Colorado 80309-0215
`One Merck Drive
`Whitehouse Station, New Jersey 08889-0100
`3 Times Square, 30tb Floor
`New York, New York 10036
`570 Lexington Avenue, 37aa Floor
`New York, New York 10022
`277 Park Avenue, 35th Floor
`New York, New York 10172
`3401 West End Avenue, Suite 300
`Nashville, Tennessee 37203
`42! Curie Boulevard
`Philadelphia, Pennsylvania 19104-6160
`636 11th Avenue
`New York, New York 10036
`Av. Ejercito Naeional No. 453
`Colonia Granada, 11520 Mexico, D.F.
`Mexico
`Washington Road
`Princeton, New Jersey 08544-1014
`One Merck Drive
`Whitehouse Station, New Jersey 08889-0100
`55 Fruit Street, Bulfinch 370
`Boston, Massachusetts 02114-2606
`
`2-
`
`PATENT
`REEL: 023861 FRAME: 0361
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 19
`
`

`

`Wendell P. Weeks
`
`Peter C. Wendell
`
`1 Riverfront Plaza
`Coming, New York 14831
`
`2884 Sand Hill Road, Suite 100
`Menlo Park, California 94025
`
`PATENT
`REEL: 023861 FRAME: 0362
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 20
`
`

`

`IN W/TNESS WHBRF~F, Memk & Co~:,~¢. causal this Re.ted Certificate of
`Ineorpora/ton to be duly e~! a~ ofNevember ~ 2009.
`
`PATENT
`REEL: 023861 FRAME: 0363
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 21
`
`

`

`.1$
`
`US
`
`MERCK & CO., INC.
`
`091828259
`
`6534506
`
`tNHIBITORS OF PRENYL-PROTEIN TRANSFERASE
`
`MERCK & CO., INC.
`
`091591631
`
`6538002
`
`CYCLOPENTYL MODULATORS OF CHEMOKINE
`RECEPTOR ACTIVITY
`
`US
`
`MERCK & CO., INC.
`
`09/659221
`
`6544213
`
`DUAL COMPARTMENT MIXING AND DISPENSING DEVICE
`
`US
`
`iMERCK & CO., INC.
`
`09/603680
`
`6544753
`
`GALANIN RECEPTOR GALR2 AND NUCLEOTIDES
`ENCODING SAME
`
`US
`
`US
`
`MERCK & CO., INC.
`
`09/756582
`
`6544967
`
`METHOD FOR INHIBITING BONE RESORPTION
`
`MERCK & CO., INC.
`
`09/698811
`
`6544982
`
`THROMB[N RECEPTOR ANTAGON[STS
`
`US
`
`MERCK & CO., INC.
`
`09/914985
`
`6544988
`
`TRYOSINE KINASE INHIBITORS
`
`US
`
`MERCK & CO., INC.
`
`091931454
`
`6545023
`
`US
`
`MERCK & CO., INC.
`
`09/764738
`
`6545036
`
`CYCLOPENTYL MODULATORS OF CHEMOKINE
`F~ECEPTOR ACTIVITY
`
`OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR
`;HYPERTENSION
`
`US
`
`MERCK & CO., INC.
`
`091060299
`
`6545137
`
`NOVEL RECEPTOR
`
`US
`
`MERCK & CO., iNC.
`
`~9/698808
`
`3548492
`
`PROCESS FOR FORMULATING OF CARBAPENEM
`ANTIBIOTIC COMPOSITIONS
`
`US
`
`US
`
`US
`
`US
`
`MERCK & CO., INC.
`
`09/765716
`
`6548535
`
`METHOD FOR TREATING OCULAR HYPERTENSION
`
`MERCK & CO.INC & MERCK SHARP & DOHME
`LIMITED
`
`091806372
`
`8552043
`
`8ENZIMIDAZOUNYL PIPERIDINES AS CGRP LIGANDS
`
`MERCK & CO., iNC.
`
`091402923
`
`6555654
`
`NOVEL RECEPTOR
`
`MERCK & CO., INC.
`
`09/558795
`
`6562592
`
`ESTROGEN RECEPTOR
`
`74
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 22
`
`

`

`US
`
`US
`
`MERCK & CO., INC.
`
`09/719878
`
`6562823
`
`[NHIBITORS OF PRENYL-PROTEIN TRANSFERASE
`
`MERCK& CO., INC.
`
`09/601708
`
`6565813
`
`VIRTUAL WELLS FOR USE tN HIGH THROUGHPUT
`SCREENING ASSAYS
`
`US
`
`MERCK& CO., INC.
`
`09/757217
`
`6566385
`
`INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
`
`I,O
`
`O’;
`
`,’,1
`
`p..<
`Zt~
`LUu-
`
`N
`
`W
`ILl
`
`VASCULAR ENDOTHELIAL CELL GROWTH FACTOR C
`SUBUNIT
`
`ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID
`DISORDERS
`
`METHOD FOR TREATING OR PREVENTING
`PSYCHOSOMATIC DISORDERS
`
`POLYMORPHIC FORM OF A TACHYKININ RECEPTOR
`ANTAGONIST
`
`iUS
`
`MERCK & CO., INC.
`
`09/699769
`
`6569434
`
`MERCK & CO., INC.
`
`09/932834
`
`=6569879
`
`us
`
`us
`
`MERCK & CO., INC.
`
`US
`
`MERCK & CO., INC.
`
`09/855408
`
`10/219386
`
`6573261
`
`5583142
`
`US
`
`MERCK & CO., INC.
`
`10/06t817
`
`5586423
`
`F~ROSINE KINASE INHIBffORS
`
`US
`
`MERCK & CO., INC. ,
`
`10/062351
`
`5586424
`
`rfROSINE KINASE INHIBITORS
`
`iUS
`
`MERCK & CO., INC.
`
`~91901266
`
`B586452
`
`MERCK & CO., INC.
`
`[}9/408361
`
`8589318
`
`IMERCK & CO., INC. & BANTU
`:~HARMACEUTICAL CO., INC.
`
`09/712368
`
`8593108
`
`MERCK & CO., INC.
`
`10/075163
`
`6593346
`
`MERCK & CO., INC.
`
`09/743742
`
`8599718
`
`MERCK & CO., INC.
`
`09/762662
`
`6602697
`
`US
`
`US
`
`US
`
`US
`
`’31 TO CA SIDE CHAIN MODIFIED NODULtSPORIC ACID
`~ALOGS
`
`&DSORPTION POWDER FOR REMOVING MERCURY FROM
`HIGH TEMPERATURE, HIGH MOISTURE GAS STREAMS
`
`NUCLEIC ACID MOLECULE ENCODING A MELANIN-
`CONCENTRATING HORMONE RECEPTOR 2 POLYPEPTID[
`
`N-CYCLOPENTYL MODULATORS OF CHEMOKINE
`RECEPTOR ACTIVITY
`
`GROWTH HORMONE SECRETAGOGUE RELATED RECEP
`TORS AND NUCLEIC ACIDS
`
`PROCESS FOR PURIFYING HUMAN PARLLOMAVIRUS
`VIRUS-LIKE PARTICLES
`
`75
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 23
`
`

`

`US
`
`MERCK & CO., INC. & BANYU
`PHARMACEUTICAL CO., INC.
`
`10/349835
`
`6605720- ~-
`
`PROCESS FOR MAKING SPIROLACTONE COMPOUND~
`
`US
`
`MERCK & CO., INC.
`
`09/429741
`
`6610692
`
`THROMBIN INHIBITORS
`
`MERCK & CO., INC.
`
`09/828325
`
`6610722
`
`INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
`
`US
`
`MERCK & CO., INC.
`
`09/920497
`
`6610822
`
`PURIRCATION PROCESS
`
`US
`
`MERCK & CO., INC.
`
`091631807
`
`6616931
`
`ROTAVIRUS VACCINE FORMULATIONS
`
`US
`
`MERCK & CO., INC.
`
`09/338409
`
`6617426
`
`0YSTEINYL PROTEASE INHIBITORS
`
`US
`
`MERCK & CO., INC.
`
`10/099672
`
`8823755
`
`us
`
`MERCK & CO., INC.
`
`091697415
`
`6630510
`
`US
`
`MERCK & CO., INC.
`
`O81962430
`
`6632625
`
`PHARMACEUTICAL TABLETS
`NOVEL SUBSTITUTED SUCCINIC ACID METALLO-BETA-
`LACTAMASE INHIBITORS AND THEIR USE IN TREATING
`BACTERIAL INFECTIONS
`
`~IUTANT OB RECEPTORS AND NUCLEOTIDES ENCODING
`THEM
`
`US
`
`MERCK & CO., INC.
`
`09/756248
`
`6632818
`
`INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
`
`MERCK & CO., INC.
`
`081996308
`
`6632823
`
`NOVEL SUBSTITUTED PYRIDINE COMPOUNDS USEFULAS~
`MODULATORS OF ACETYLCHOLINE RECEPTORS
`
`VIERCK & CO., INC.
`
`09/422143
`
`6632836
`
`CARBOCYCLIC POTASSIUM CHANNEL INHIBITORS
`
`MERCK & CO., INC.
`
`09~02285
`
`6638347
`
`MERCK & CO., iNC.
`
`09/836716
`
`6638930
`
`CARBON-BASED ADSORPTION POWDER CONTAINING
`CUPRIC CHLORIDE
`
`MORPHOLINE AND THIOMORPHOUNE TACHYKININ
`RECEPTOR ANTAGONISTS
`
`~ERCK & CO., INC. & BANYU
`:~HARMACEUTICAL CO., INC.
`
`10/228250
`
`6638942
`
`SPIRO-INDOLINES AS Y5 RECEPTOR ANTAGONISTS
`
`us
`
`US
`
`us
`
`us
`
`us
`
`76
`
`l,U
`LU
`
`Merk Sharp & Dohme Corp. Exhibit 2010
`Mylan Pharmaceuticals Inc. v. Merk Sharp & Dohme Corp.
`IPR2020-00040
`Page 24
`
`

`

`US
`,, ,, , ,
`
`MERCK & CO., INC.
`
`10/000537
`
`6639071
`
`!US
`
`MERCK & CO., INC.
`
`09/718223
`
`6642237
`
`MERCK & CO., INC.
`
`09/762661
`
`6645726
`
`US
`
`JS
`
`MERCK& CO., INC.
`
`09/831228
`
`6645738
`
`MERCK& CO., INC.
`
`09/317789
`
`5645939
`
`US
`
`MERCK & CO., iNC.
`
`091045885
`
`6645961
`
`US
`
`MERCK & CO., INC.
`
`10/205634
`
`6645974
`
`MERCK & CO., INC.
`
`09/961841
`
`6645997
`
`MERCK & CO., INC.
`
`101197003
`
`664613O
`
`r,,,,,
`
`o
`
`Zn~
`i~1u,.
`
`D.~
`
`.5
`W
`Ill
`
`PROCESS FOR THE CRYSTALLIZATION OF A REVERSE
`TRANSCRIPTASE !NHIBITOR USING ANANTI-SOLVENT
`
`GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-
`PIPERAZINEPENTANAMIDES AND USES THEREOF
`
`CANINE GROWTH HORMONE SECRETAGOGUE
`RECEPTOR
`
`DNA MOLECULES ENCODING THE MELANOCORTIN 5
`RECEPTOR PROTEIN FROM RHESUS MONKEY
`
`SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL
`ADHESION
`INHIBITORS
`
`DRY GRANULATION FORMULATION FOR AN HIV
`PROTEASE INHIBITOR
`
`ANDROGEN RECEPTOR MODULATORS AND METHODS OF
`USE THEREOF
`
`BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE
`TREATMENT OF DIABETES AND LIPID DISORDERS
`
`PROCESS TO CHIRAL INTEGRIN ANTAGONIST BETA-
`AMINO ACID INTERMEDIATE
`
`US
`
`US
`
`~US
`
`US
`
`US
`
`US
`
`us
`
`us
`
`~ERCK & CO. INC, & MERCK FROSST CANADA,
`INC.
`
`39/261034
`
`6649649
`
`~METHOD OF TREATING COLONIC ADENOMAS
`
`MERCK & CO., INC.
`
`08/450273
`
`5653097
`
`MERCK & CO., INC.
`,,, ,
`
`,
`
`,
`
`09/176492
`
`3656719
`
`MERCK & OO., INC.
`
`09/892985
`
`~64375
`
`MERCK & CO., INC.
`
`09!067432
`
`6673831
`
`MERCK & CO., INC.
`
`10/342380
`
`6673935
`
`HUMAN CALCIUM CHANNEL COMPOSmONS AND
`’vIETHODS
`
`SERUM-FREE, LOW-PROTEIN MEDIA FOR ROTAVIRU$
`VACCINE PR